Skip to main
VSTM

Verastem (VSTM) Stock Forecast & Price Target

Verastem (VSTM) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Verastem is a promising company with a strong innovative pipeline targeting critical signaling pathways in cancer, such as RAF/MEK and FAK inhibition. With a Phase 3 trial for their KRAS G12D PDAC treatment underway in China, the company could potentially gain a market advantage in this area. The favorable initial data for VS-7375, along with the potential for Avutometinib to become a new standard of care, points to a positive outlook for the company's future success and potential financial growth.

Bears say

Verastem is a company with a limited addressable market in NSCLC due to the prevalence of the KRAS G12D mutation and the safety profiles of their potential treatment options not standing out compared to competitors. Their PDAC analysis provided some reassurance, but overall the readout will focus more on safety rather than early efficacy in a small sample patient count. In addition to their lead program for low-grade serous ovarian cancer, the company has several other notable programs in development, but their success is uncertain and launch may not occur until 2025.

Verastem (VSTM) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Verastem and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Verastem (VSTM) Forecast

Analysts have given Verastem (VSTM) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Verastem (VSTM) has a Strong Buy consensus rating as of May 1, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $16.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $16.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Verastem (VSTM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.